Search tips
Search criteria 


Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Clin Pathol. 1998 June; 51(6): 432–437.
PMCID: PMC500745

Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).


AIMS: To investigate whether plasma cell expression of early B cell, late B cell/preplasma cell, T cell, and myelomonocytic antigens or myeloma associated lymphocytic infiltrates correlated with prognosis in bone marrow biopsy specimens of patients with multiple myeloma. METHODS: Bone marrow biopsy specimens of 23 patients with multiple myeloma were investigated for plasma cell expression and interstitial lymphocyte expression of T cell related antigen CD45RO (UCHL-1). RESULTS: Eight patients showed plasma cell expression of CD45RO and 16 showed increased tumour infiltrating CD45RO positive lymphocytes, which were correlated with poor survival by multivariate analyses (p = 0.005 and p = 0.04, respectively). B cell antigens (MB2, CD20) but no T cell specific antigens (CD3) or T cell receptor gene rearrangements were expressed by plasma cells in CD45RO positive myelomas. Of 16 patients with myeloma who had increased tumour infiltrating CD45RO positive lymphocytes, four had interstitial lymphocyte expression of B cell antigens and two had interstitial lymphocyte expression of the T cell specific antigen CD3. CONCLUSIONS: The recognition of plasma cell expression of CD45RO and increased interstitial CD45RO lymphocytes in bone marrow biopsy specimens of patients with multiple myeloma is an adverse prognostic finding not indicative of an aberrant T cell phenotype or genotype; it is consistent with B cell/pre-plasma cell antigen expression by myeloma cells and their lymphocytic precursors.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993 Sep 1;178(3):1023–1031. [PMC free article] [PubMed]
  • MacKenzie MR, Lewis JP. Cytogenetic evidence that the malignant event in multiple myeloma occurs in a precursor lymphocyte. Cancer Genet Cytogenet. 1985 May;17(1):13–20. [PubMed]
  • Jensen GS, Mant MJ, Belch AJ, Berenson JR, Ruether BA, Pilarski LM. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood. 1991 Aug 1;78(3):711–719. [PubMed]
  • Jensen GS, Belch AR, Kherani F, Mant MJ, Ruether BA, Pilarski LM. Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD11b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol. 1992 Dec;36(6):843–853. [PubMed]
  • Goto H, Shimazaki C, Ashihara E, Ohkawa K, Oku N, Inaba T, Murakami S, Fujita N, Nakagawa M. Effects of interleukin-3 and interleukin-6 on peripheral blood cells from multiple myeloma patients and their clinical significance. Acta Haematol. 1992;88(2-3):129–135. [PubMed]
  • Reibnegger G, Wachter H, Krainer M, Ludwig H, Herold M, Huber H. Hyperreactive cellular immunity in multiple myeloma. Blood. 1992 Apr 15;79(8):2174–2176. [PubMed]
  • Massaia M, Attisano C, Peola S, Montacchini L, Omedé P, Corradini P, Ferrero D, Boccadoro M, Bianchi A, Pileri A. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood. 1993 Sep 15;82(6):1787–1797. [PubMed]
  • Osterborg A, Janson CH, Bergenbrant S, Holm G, Lefvert AK, Wigzell H, Mellstedt H. Peripheral blood T lymphocytes in patients with monoclonal gammopathies: expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti-V gene-restricted antibodies. Eur J Haematol. 1991 Sep;47(3):185–191. [PubMed]
  • Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood. 1995 Jan 15;85(2):436–447. [PubMed]
  • Omedé P, Boccadoro M, Gallone G, Frieri R, Battaglio S, Redoglia V, Pileri A. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood. 1990 Oct 1;76(7):1375–1379. [PubMed]
  • Mellstedt H, Holm G, Pettersson D, Björkholm M, Johansson B, Lindemalm C, Peest D, Ahre A. T cells in monoclonal gammopathies. Scand J Haematol. 1982 Jul;29(1):57–64. [PubMed]
  • Durie BG, Grogan TM. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood. 1985 Jul;66(1):229–232. [PubMed]
  • Grogan TM, Durie BG, Spier CM, Richter L, Vela E. Myelomonocytic antigen positive multiple myeloma. Blood. 1989 Feb 15;73(3):763–769. [PubMed]
  • Spier CM, Grogan TM, Durie BG, Richter LC, Vela E, Frutiger Y, Rangel CS. T-cell antigen-positive multiple myeloma. Mod Pathol. 1990 May;3(3):302–307. [PubMed]
  • Petruch UR, Horny HP, Kaiserling E. Frequent expression of haemopoietic and non-haemopoietic antigens by neoplastic plasma cells: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histopathology. 1992 Jan;20(1):35–40. [PubMed]
  • Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. [PubMed]
  • Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985 Feb;65(2):305–310. [PubMed]
  • Epstein J, Xiao HQ, He XY. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med. 1990 Mar 8;322(10):664–668. [PubMed]
  • Poppema S, Lai R, Visser L. Monoclonal antibody OPD4 is reactive with CD45RO, but differs from UCHL1 by the absence of monocyte reactivity. Am J Pathol. 1991 Oct;139(4):725–729. [PubMed]
  • Wan JH, Trainor KJ, Brisco MJ, Morley AA. Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction. J Clin Pathol. 1990 Nov;43(11):888–890. [PMC free article] [PubMed]
  • Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood. 1991 Jul 1;78(1):192–196. [PubMed]
  • Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M, Campana D, van Camp B, Janossy G. Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest. 1985 Sep;76(3):1243–1251. [PMC free article] [PubMed]
  • Grogan TM, Durie BG, Lomen C, Spier C, Wirt DP, Nagle R, Wilson GS, Richter L, Vela E, Maxey V, et al. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood. 1987 Oct;70(4):932–942. [PubMed]
  • Brown RD, Joshua DE, Ioannidis RA, Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust N Z J Med. 1989 Jun;19(3):226–232. [PubMed]
  • Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med. 1989 Apr 1;110(7):521–525. [PubMed]
  • Pilarski LM, Mant MJ, Ruether BA. Pre-B cells in peripheral blood of multiple myeloma patients. Blood. 1985 Aug;66(2):416–422. [PubMed]
  • Kay NE, Oken MM, Bone N, Kyle RA, Greipp P, Van Ness B, Leong T. Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group. Blood. 1995 Nov 15;86(10):4000–4001. [PubMed]
  • Mellstedt H, Hammarström S, Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol. 1974 Jul;17(3):371–384. [PubMed]
  • Bast EJ, van Camp B, Reynaert P, Wiringa G, Ballieux RE. Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol. 1982 Mar;47(3):677–682. [PubMed]
  • Jensen GS, Poppema S, Mant MJ, Pilarski LM. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol. 1989;1(3):229–236. [PubMed]
  • Gloghini A, De Paoli P, Gaidano G, Franceschi S, Carbone A. High frequency of CD45RO expression in AIDS-related B-cell non-Hodgkin's lymphomas. Am J Clin Pathol. 1995 Dec;104(6):680–688. [PubMed]
  • Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE, Selbach J, Wacker G, Deicher H. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol. 1992 Mar;64(3):132–139. [PubMed]
  • Dehou MF, Schots R, Lacor P, Arras N, Verhavert P, Klöppel G, van Camp B. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1990 Sep;94(3):287–291. [PubMed]
  • Barlogie B, Epstein J, Alexanian R. Genotypic and phenotypic characteristics of multiple myeloma. Hematol Oncol. 1988 Apr-Jun;6(2):99–102. [PubMed]
  • Durie BG. The biology of multiple myeloma. Hematol Oncol. 1988 Apr-Jun;6(2):77–81. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group